Natural Killer Cells

[Oncoimmunology] Researchers deeply investigated the impact of KIR, HLA class I, and CD16 genotypes on rituximab-dependent NK cell responses in both an in vitro cellular model from healthy blood donors and ex vivo rituximab-treated non-Hodgkin lymphoma patients.

[Scientific Reports] Participants playing up to 540 in cumulative match time and less than 30 min in each single match during the observation period formed the control group. White blood cell phenotyping and creatine kinase plasma activity analyses were performed.

[Journal of Experimental Medicine] The authors discovered that YTHDF2, a well-known N6-methyladenosine (m6A) reader, was upregulated in NK cells upon activation by cytokines, tumors, and cytomegalovirus infection.

[Scientific Reports] A porcine endothelial cell was characterized and immortalized for genetic modification. Five genes including GGTA1, CMAH, β4galNT2, SLA-I α chain, and β2-microglobulin that are responsible for the production of major xenoantigens were sequentially disrupted in immortalized porcine endothelial cells using CRISPR/Cas9 technology.

[Journal of Clinical Investigation] Researchers showed that glioblastoma stem cells, but not normal astrocytes, were sensitive to lysis by healthy allogeneic natural killer cells in vitro.

[Signal Transduction and Targeted Therapy] Investigators found that the nonclassical histocompatibility antigen HLA-G desensitized breast cancer cells to trastuzumab by binding to the natural killer cell receptor KIR2DL4.